Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gestiva Preterm Birth Drug Could Be Approved In October

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA granted a six-month priority review to Adeza’s NDA for the progesterone product under the 505(b)(2) pathway.

You may also be interested in...



KV Purchases Hologic Premature Birth Prevention Candidate; Sale Contingent On FDA Approval

NDA approval is expected in late 2008 for Gestiva, which has been under review since April 2006.

KV Purchases Hologic Premature Birth Prevention Candidate; Sale Contingent On FDA Approval

NDA approval is expected in late 2008 for Gestiva, which has been under review since April 2006.

Adeza’s Gestiva Review To Consider The Validity Of Pivotal Trial’s Primary Endpoint

FDA’s Reproductive Health Drugs Advisory Committee will discuss the preterm birth agent during an Aug. 29 meeting.

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel